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Abstract: Advances in biotechnology, better understanding of pathophysiological processes, 
as well as the identification of an increasing number of molecular markers have facilitated the 
use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, 
a rapidly growing number of these substances have also emerged in the field of oncology. This 
review will summarize the currently approved monoclonal antibodies used for the treatment 
of solid tumors with a focus on their clinical application, biological background, and currently 
ongoing trials.
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Introduction
Since the first description of monoclonal antibodies (mAbs) by Kohler and Milstein in 
1975,1 numerous advances in molecular biology and biotechnology have streamlined 
the identification, genetic manipulation, and recombinant production of such antibodies. 
Over the past decade the use of antibodies has spread into different fields in medicine, 
such as autoimmune diseases, hematological disorders, cardiovascular diseases, infectious 
diseases, and diagnostics.2–4 Also, in the treatment of solid human tumors, biological thera-
peutics have emerged and gained importance for a growing number of cancer entities.
In the treatment of solid human tumors, biological therapeutics have also emerged 
and gained importance for a growing number of cancer forms. In contrast to conven-
tional therapeutics such as chemotherapeutics or radiation, which both impose a high 
burden on nontumor tissue, the use of biological therapeutics aims at more specific, 
targeted therapy.
The concept of targeted therapy was facilitated by greater understanding of the 
biological pathways involved in the pathogenesis of cancer, and subsequently iden-
tification of cell surface antigens and bioactive molecules.5–7 A rather specific, and 
thus restrictive, expression pattern of these antigens and molecules in human tissue 
enables locally-focused targeting of antibodies to tumor tissue itself, as well as to 
nonneoplastic cells and substances relevant for tumor biology.
The introduction of mAbs in tumor therapy had a significant impact on pathological 
processes, particularly malignancies of solid and hematological origin. In particular, 
the use of mAbs has been established as mono, combination, first- and second-line, as 
well as palliative therapies. Their selectivity and specificity, unique pharmacokinetics, 
and ability to engage and activate the immune system   differentiate these biologics 
from other small molecule anticancer drugs.Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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This review summarizes the currently established 
  biological therapeutics for treating solid tumors, with empha-
sis on the mAbs that have been approved by the United States 
Food and Drug Administration (FDA) for clinical use, as well 
as ongoing phase III studies and current Fc fusion proteins 
as of June 2011. Furthermore, the focus is on the targeted 
proteins and observed treatment effects associated with each 
antibody, the registration trials for their approved indications, 
and new emerging indications.
Structure and nomenclature
Biologically targeted therapy with mAbs has become an 
attractive treatment strategy for both solid tumors and 
hematological malignancies. The hybridoma technology 
can produce antibodies that are products of single antibody-
producing cells, and thus have a single variable region associ-
ated with one constant region, in other words mAbs.1
The first therapeutic mAbs were derived from immuniz-
ing mice against epidermal growth factor receptor (EGFR) 
  proteins. These murine mAbs (suffix “-omab”) were associ-
ated with activation of the immune system, and development 
of antimurine antibody responses that induced severe anaphy-
laxis, which decreased the circulating half-life and finally led to 
reduced efficacy.8,9 As a consequence, chimerized (“-ximab”) 
antibodies were generated by genetically replacing the human 
constant sequence with a variable murine domain with anti-
genic activity. The production of fully humanized mAbs 
(“-zumab”), replacing murine residues in complementarity 
determining regions with human sequences, finally reduced 
immunogenicity and improved their efficacy and safety for 
use in humans.10 These technological advances resulted in 
molecules with a long circulating half-life that, depending 
on the Fc selection, interact with human complement and/or 
effector cells to produce cell-mediated cytotoxicity or anti-
body dependent cell-mediated cytotoxicity (ADCC).
The mechanisms of action may be explained by an   induction 
and concentration of host defense mechanisms, the neutraliza-
tion of biologically active substances, and/or impairment of 
specific intracellular pathways. These effects may result in 
target-oriented immune response, reduced tumor proliferation 
itself, and/or increased efficacy of radio- or chemotherapy.
Limitations and side effects
While mAb-based therapies offer novel strategies to   target cyto-
toxicity exclusively to malignant cells, successful   application 
with maximal efficacy is often limited by   common obstacles. 
The therapeutic benefit of mAbs may be limited by low or het-
erogeneous expression of target antigens by tumor cells, high 
background expression of antigens by tumor cells, and host 
antibody immune responses to mAb binding. These problems 
may be aggravated by, for example, compensatory responses 
of affected cells to mAb treatment in terms of an upregulation 
of alternative or primary redundant signaling molecules. This 
phenomenon may represent one escape mechanism resulting in 
secondary tumor regrowth and/or increasing angiogenesis.
Additionally, physical obstructions for antibody binding 
such as endothelial, interstitial, and epithelial barriers com-
plicate the delivery of mAbs to target cells and thus reduce 
therapeutic efficacy.11 To overcome this obstacle, antibody 
fragments lacking the Fc region have been developed. The 
smaller molecule size results in improved tissue permeabil-
ity, however, it also leads to reduced plasma half-life due to 
increased renal elimination. Furthermore, the lack of an Fc 
region excludes a direct activation of the complement system 
and consequently direct cytotoxic activity.
A wide range of side effects of mAb therapy has been 
reported, which may be caused by antibody binding to 
nonneoplastic tissue, thus interfering with physiological 
  processes and inducing autoimmune responses. Furthermore, 
the desired immune response with a resulting secretion of 
proinflammatory cytokines may induce severe symptoms as 
fever, malaise, and headaches.
mAbs
Current clinical applications  
for solid tumors
The following antibodies in clinical use are summarized in 
Table 1.
Trastuzumab (Herceptin®)
Trastuzumab is a humanized mAb that recognizes an epitope 
on the extracellular domain of the human EGFR-2 (HER2/
neu, c-erbB2).12 Several studies reported that amplification 
of the erbB2 proto-oncogene was associated with overexpres-
sion of HER2 in tumor cells in approximately 25% of breast 
cancers, adenocarcinomas of the ovary, prostate, lung, and 
gastrointestinal tract.13,14
To prolong the systemic half-life of trastuzumab the 
idiotopes from the hypervariable region that bind HER2 
with high affinity and avidity were linked with elements of 
human immunoglobulin (Ig) G1 antibody. Due to the human 
IgG1 constant regions of the humanized mAb, trastuzumab is 
very effective for inducing ADCC against breast cancer cells 
that overexpress HER2 in vitro but is ineffective for induc-
ing cell-mediated cytotoxicity. Trastuzumab was granted 
regulatory approval in 1999 as monotherapy for metastatic Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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breast cancer and thus became the first mAb approved based 
on activity in a solid tumor.2
In two large trials with HER2-overexpressing breast 
cancer patients having had little or no prior chemotherapy, 
the combination of chemotherapy with trastuzumab led to a 
higher objective response rate, a longer time to progression, 
longer duration of response, and greater overall survival 
compared to chemotherapy alone.15
In 2006, trastuzumab became the only tyrosine kinase-
targeted agent approved for the adjuvant treatment of solid 
tumors, based on pooled data from .3000 node-positive, or 
high-risk node-negative patients from two clinical trials.16
Since 2008, trastuzumab has been released as a single 
agent in second-line therapy in metastatic breast cancer. The 
most severe toxicities associated with HER2/neu-targeting 
antibodies are cardiomyopathy and pulmonary disorders.17
Bevacizumab (Avastin®)
Bevacizumab is a humanized IgG1 mAb that blocks binding 
of vascular endothelial growth factor (VEGF) to its receptors 
VEGFR1 and VEGFR2 on vascular endothelium. VEGF is 
regarded as the key regulator of tumor-associated   angiogenesis, 
and is produced by most types of malignant cells. While the 
initial hypothesis that antiangiogenic agents lead to starva-
tion of tumor tissue has been revised in favor of a structural 
reorganization of tumor vessels during   antiangiogenic treat-
ment, increased responsiveness to radiation and chemotherapy 
in combination with antiVEGF agents has been reported.
Bevacizumab was originally approved in 2004 as the 
first VEGF inhibitor for first-line treatment of metastatic 
colorectal cancer (mCRC) after promising results in a 
key trial.18 In this phase III trial involving 813 patients with 
mCRC, 402 patients received irinotecan, fluorouracil, and 
leucovorin (IFL) plus bevacizumab, while 411 received 
IFL plus placebo. Overall survival significantly increased 
from 15.6 months in the control group (IFL plus placebo) to 
20.3 months in the IFL/bevacizumab group.
Based on a randomized, multicenter trial that proved 
longer overall survival and overall response rate with 
  bevacizumab/oxaliplatin, fluorouracil, and leucovorin com-
pared to   oxaliplatin, fluorouracil, and leucovorin monotherapy 
in patients with mCRC, bevacizumab was approved as a 
second-line agent for this indication.19
Subsequently, bevacizumab was approved for first-line 
combination treatment of advanced and metastatic nonsmall 
cell lung cancer in 2006 and for combination therapy with 
paclitaxel in metastatic breast cancer in 2008 by the FDA.20,21
Final results of the phase III study (AVOREN) conducted 
in patients with metastatic renal cell carcinoma who had 
  undergone nephrectomy showed a median progression-free 
survival of 10.2 months for the bevacizumab plus interferon arm 
compared to 5.4 months for the interferon and placebo arm.22
In 2009, the FDA approved bevacizumab as a second-
line treatment for patients with recurrent glioblastoma after 
prior standard therapy.23 This approval was not given by the 
European Medicines Agency due to the weakness of the 
published data. Currently, a multicentric phase III trial is 
underway for glioblastoma (AVAGLIO).
Due to the widespread expression of VEGF, a large range 
of side effects has been reported. Among those, the most 
frequent are hypertension, skin changes, abdominal pain, 
and general weakness.18,21,23,24
Cetuximab (Erbitux®) and panitumumab (vectibix®)
Observed overexpression of EGFR in colorectal carcino-
mas led to the development of antiEGFR mAb such as 
cetuximab and panitumumab that bind to EGFRs and com-
petitively block ligand binding. As a consequence, blocking 
phosphorylation and activation of several tyrosine kinases 
intercepts signal transduction, resulting in inhibition of 
tumor growth and induction of apoptosis in vitro.25
Cetuximab, a chimeric monoclonal IgG1 antibody, 
develops its antitumor efficacy through specific targeting of 
EGFRs, inducing receptor internalization and degradation 
with downregulation of EGFR expression. The therapeutic 
mechanism is mainly the induction of ADCC rather than 
immunotherapeutical effects.26
Cetuximab is predominantly implemented as an additional 
agent to chemo- and radiotherapy in mCRC, as well as head 
Table 1 Food and Drug Administration approved monoclonal 
antibodies for therapy of solid tumors
Antibody Trade name Target Indication
Cetuximab Erbitux® EGFR CRC (m), SCCHN 
(loc ad, rec)
Panitumumab vectibix® EGFR CRC (m)
Trastuzumab Herceptin® HER2 BC (ad, m), AC of 
GE junction
Bevacizumab Avastin® vEGF CRC (m), SCCHN 
(loc ad, rec), BC 
(m), RCC (ad), 
glioblastoma
Girentuximab Rencarex® Carbonic 
anhydrase iX
RCC
ipilimumab Yervoy® CTLA-4 MM (met)
Abbreviations:  AC,  adenocarcinoma;  ad,  advanced;  BC,  breast  cancer;  CRC, 
colorectal  cancer;  CTLA-4,  cytotoxic T  lymphocyte  antigen-4;  EGFR,  epidermal 
growth  factor  receptor;  GE,  gastroesophageal;  HER2,  human  epidermal  growth 
factor  receptor-2;  loc  adv,  locally  advanced;  m,  metastatic;  MM,  malignant 
melanoma;  RCC,  renal  cell  carcinoma;  rec,  recurrent;  SCCHN,  squamous  cell 
carcinoma of the head and neck; vEGF, vascular endothelial growth factor.Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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and neck cancer. It was first approved for the treatment of 
refractory mCRC in combination with irinotecan in patients 
who had EGFR-detectable, irinotecan-refractory mCRC.27
Following a continuative study that showed a reduced risk 
for disease progress of mCRC using cetuximab in combination 
with irinotecan, folinic acid, and 5-fluorouracil, cetuximab 
was approved as a first-line treatment for CRC in 2009.28
It also gained FDA approval for combination with radio-
therapy to treat locally advanced squamous cell carcinoma 
of the head and neck (SCCHN),29,30 as well as second-line 
monotherapy in recurrent metastatic SCCHN.31
One randomized, open-label ongoing phase III multicenter 
study (NCT01309126) is evaluating overall survival of patients 
with wild-type kRAS CRC after treatment with a combination 
of cetuximab and Imprime PGG® or cetuximab alone. The 
study started in April 2011 and will be completed in September 
2012 after an estimated enrollment of 795 patients.
Serious cetuximab-related toxicities include hypersensi-
tivity, infusion-related reactions, and interstitial lung disease 
including pulmonary hemorrhage.32
Panitumumab is a fully humanized IgG2 antibody that 
like cetuximab interacts with the EGF-1 receptor, impairing 
signal transduction and subsequently leading to less cell pro-
liferation and resistance to apoptosis. However, panitumumab 
does not induce EGFR degradation.
Panitumumab efficacy was evaluated in four phase III 
trials.24,33–35 It was granted regulatory approval as the first 
fully human mAb based on a randomized phase III trial33 
where 463 patients with mCRC who had received both 
panitumumab and best supportive care (BSC) showed an 
improvement in their overall response rate and progression-
free survival compared to treatment with BSC alone. 
Response rates in the combined therapy group were even 
higher in patients positive for wild-type kRAS (an   intracellular 
  molecule involved in EGF signaling) whereas these drugs 
had no effect in patients with mutated kRAS.36 There was 
no proof of benefit for combination of panitumumab with 
chemotherapy in first-line treatment of mCRC.37
The most commonly reported adverse effects of antiEGFR 
mAbs are explained by the widespread expression of EGFR on 
various tissues. These include acneiform rash, malaise, hypo-
magnesemia, pneumonia, and headaches. Compared to cetux-
imab, fewer common adverse events, especially dermatological 
toxicity, accompanied treatment with panitumumab.38
In conclusion, cetuximab and panitumumab are currently 
part of standard therapy for mCRC, although results from 
ongoing trials might elucidate further treatment indications.
ipilimumab (Yervoy®)
Ipilimumab, a novel human IgG1 mAb inhibiting the 
cytotoxic T lymphocyte antigen-4, has been evaluated for 
treating metastatic melanoma. FDA granted priority review 
for ipilimumab in March 2011 as the first agent indicated 
for unresectable, metastatic, or untreated stage III or IV 
melanoma in adults.
Recently, results of a phase III randomized, double-blind 
trial were published demonstrating an overall survival ben-
efit for patients with metastatic melanoma who were treated 
with ipilimumab as monotherapy or with the glycoprotein 
100 vaccine.39 The trial did not show the suggested syner-
gistic effect of glycoprotein 100, nor that the efficacy of 
ipilimumab was altered by the immune response. Thus, the 
FDA approved ipilimumab as monotherapy in unresectable, 
metastatic, or untreated stage III or IV melanoma in adults.
Cytotoxic T lymphocyte antigen-4-inhibiting mAbs may 
induce autoimmunity, enterocolitis, and hypopituitarism.17
Novel mAbs currently being investigated 
in phase iii trials
Girentuximab (Rencarex®)
Girentuximab is an IgG1 kappa light-chain antibody that 
binds to carbonic anhydrase IX (G250-antigen), a cell surface 
antigen expressed in 95% of clear cell renal cell carcinoma. 
The proposed mechanism of action is increased stimulation 
of natural killer cells with activity focused on tumor cells 
via ADCC.
In phase I/II studies, the combination of girentuximab 
with low-dose interferon-alpha in patients with progres-
sive metastatic renal cell carcinoma demonstrated clinical 
benefit, a good response rate, and significant prolongation 
of the median survival time (30%) in more than 130 treated 
patients.40
For patients with primary clear cell renal cell carcinoma, 
a phase III trial (NCT00087022) using girentuximab is 
  currently in progress and will end in 2013.
To date, no serious adverse event related to the study 
medication has been published described for Rencarex in the 
clinical phase I/II trials. Adverse events mainly compromised 
fever, flu-like syndromes, and headache.40
Zalutumumab
Zalutumumab, a human IgG1 mAb that targets EGFR, 
is undergoing evaluation in an open-label, randomized 
phase III study (NCT00382031) for treating patients with 
incurable SCCHN who have failed standard platinum-based 
  chemotherapy. Previous studies combining zalutumumab and Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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BSC, compared to only BSC, resulted in improved median 
overall survival from 5.2 to 6.7 months.41
Another ongoing phase III study (primary completion date: 
January 2012; NCT00496652) aims to determine whether 
addition of the fully human EGFR antibody zalutumumab to 
primary curative radiotherapy increases locoregional control 
in SCCHN. Enrollment is around 600 patients and the esti-
mated study completion date is   September 2016.
As mentioned above, the expression pattern of EGFR 
may lead to adverse effects which might be similar to that 
of other EGFR antibodies.
Tremelimumab
Tremelimumab is a fully human anticytotoxic T lymphocyte 
antigen-4 IgG2 antibody that modulates the immunological 
response using the same mechanism as ipilimumab.42 The 
advantage of tremelimumab over ipilimumab is a signifi-
cantly longer half-life.
Tremelimumab failed to show a significant improvement 
in overall survival versus chemotherapy alone in a phase III 
trial for surgically incurable metastatic melanoma patients 
without prior chemotherapy for metastatic disease.43 The 
study was discontinued after the interim analysis of treme-
limumab compared to chemotherapy with dacarbazine or 
temozolomide (11.8 months to 10.7 months).44 One ongoing 
trial studying the side effects and best dose of tremelimumab 
together with a CD40 agonist mAb CP-870 in 893 patients 
with metastatic melanoma has an estimated study completion 
date in March 2013 (NCT01103635).
In a phase II trial of tremelimumab a large proportion of 
patients (77%) developed treatment-related adverse events, 
with 19% showing serious adverse events including endocrine 
dysfunctions and colitis.44
Necitumumab
Necitumumab (IMC-11F8) is an EGFR-targeting IgG1 mAb 
which is currently being evaluated in two phase III trials for 
treating nonsquamous stage IIIB or IV nonsmall cell lung 
cancer. An open-labeled, randomized, active-controlled study 
(NCT00982111) is comparing the effect of necitumumab 
in combination with standard chemotherapy with standard 
chemotherapy alone. Data will be collected from 947 esti-
mated patients until October 2011 with an estimated study 
completion date in May 2012.
Farletuzumab
Farletuzumab is a humanized IgG1 mAb that targets 
human folate receptor alpha, which is expressed in most 
epithelial ovarian cancers. Farletuzumab administered as a 
  monotherapeutic agent or in combination with carboplatin 
and taxane in patients with platinum-sensitive relapsed 
epithelial ovarian cancers showed normalization of the bio-
marker CA125 as an indirect sign of disease response.
A current phase III study (NCT00849667) in initially 
platinum-sensitive relapsed ovarian cancer patients is com-
paring farletuzumab, combined with carboplatin and taxane, 
to chemotherapy alone. The estimated study completion date, 
with 900 patients, is September 2012.45
Another randomized, double-blind phase III trial 
(NCT00738699) is being conducted to find out whether 
farletuzumab increases the efficacy and safety of paclitaxel 
in refractory relapsed ovarian cancer. In addition, the safety 
of farletuzumab, carboplatin, and pegylated liposomal 
doxorubicin combination in patients with platinum-sensitive 
ovarian cancer is being assessed in an ongoing nonrandom-
ized phase III trial (NCT01004380).
Trastuzumab emtansine
Trastuzumab emtansine is an immunoconjugate formed by 
conjugation of trastuzumab to cytotoxic maytansinoid DM1 
that targets HER2.
A current randomized, multicenter, two-arm, open-label 
study is evaluating the efficacy and safety of trastuzumab 
emtansine in comparison to treatment of the physician’s 
choice in patients with metastatic or nonresectable locally 
advanced/recurrent HER2-positive breast cancer who have 
received at least two prior regimens of HER2-directed 
therapy. The estimated completion date for the primary 
outcome measure is April 2015.
Data from two additional phase III studies will compare 
trastuzumab emtansine to the combination of capecitabine and 
lapatinib in patients with HER2-positive, locally advanced, or 
metastatic breast cancer in adult patients who have received 
prior treatment with trastuzumab (NCT00829166). The 
estimated primary completion date for 580 enrolled patients 
is August 2013.
One  randomized,  three-arm,  multicenter  study 
(NCT01120184) is evaluating the efficacy and safety of 
trastuzumab emtansine with pertuzumab, or trastuzumab 
emtansine with placebo, versus the combination of trastu-
zumab plus taxane (docetaxel or paclitaxel) in patients with 
HER2-positive breast cancer. This started in July 2010, and 
the estimated primary completion date is July 2017.
Pertuzumab
Pertuzumab is a humanized antiHER2 IgG1, and the first of 
its kind in a group of agents inhibiting HER dimerization by Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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binding to the dimerization domain of HER2. The resulting 
inhibition of HER2 forming a complex with other HER 
receptors may result in slowed tumor growth.46
Currently, three phase III studies are evaluating single 
treatment by pertuzumab or combination therapy in previ-
ously untreated HER2 positive metastatic breast cancer 
patients. A phase III study (NCT01120184) is examin-
ing the combination of pertuzumab and trastuzumab 
emtansine. Another phase III study (NCT00567190) is 
evaluating the safety and efficacy of pertuzumab, trastu-
zumab, and docetaxel compared to trastuzumab, docetaxel, 
and a placebo. The estimated primary completion date is 
March 2012.
The purpose of another ongoing randomized, double-
blind phase III study (NCT01358877) is to assess pertu-
zumab in addition to chemotherapy plus trastuzumab as an 
adjuvant treatment therapy in patients with operable HER2-
positive primary breast cancer. After surgery, patients 
are randomized to pertuzumab or a placebo. Starting in 
October 2011, the estimated primary completion date is 
July 2024.
Ramucirumab
Ramucirumab is a human IgG1 mAb that, similar to bevaci-
zumab, targets the VEGF/VEGFR system and consequently 
tumor angiogenesis. Unlike bevacizumab, which binds 
VEGF, ramucirumab binds to VEGFR2. It is being currently 
evaluated in six phase III trials.
A randomized, double-blinded study is comparing 
ramucirumab and BSC versus a placebo and BSC in patients 
with adenocarcinomas of the gastroesophageal junction 
(NCT00917384). Starting in October 2009, with an estimated 
enrollment of 315 patients, the predicted primary completion 
date is May 2012.
A second ongoing phase III randomized, multicenter 
double-blind, placebo-controlled trial (NCT01170663) 
with 663 enrolled patients is comparing paclitaxel with 
or without ramucirumab in metastatic gastric adenocar-
cinoma after first-line treatment. The final data collec-
tion date for the primary outcome measure is May 2013. 
Further ongoing phase III trials include treatment options 
with addition of ramucirumab to irinotecan, folinic acid, 
and 5-fluorouracil chemotherapy in second-line mCRC 
(NCT01183780) or administration of ramucirumab   versus 
a placebo as second-line treatment in patients with hepa-
tocellular carcinoma following first-line therapy with 
sorafenib (NCT01140347, estimated study completion 
date: December 2012).
The combination of ramucirumab with docetaxel versus 
docetaxel plus a placebo in the treatment of stage IV nonsmall 
cell lung cancer is currently being evaluated in a randomized, 
double-blind phase III study (NCT01168973). The estimated 
patient enrollment is 1242, and the study completion date is 
expected in June 2014.
The effects of docetaxel and ramucirumab for previ-
ously untreated patients with HER2-negative breast can-
cer are being evaluated in a multicenter, multinational, 
  randomized, double-blind, placebo-controlled phase III study 
(NCT00703326). The estimated enrollment is 1113 patients 
and the predicted completion date is August 2015.
Catumaxomab (Removab®)
Catumaxomab is a trifunctional antibody with two binding 
sites and a functional Fc domain. It targets the epithelial 
cell adhesion molecule as well as the CD3 receptor on 
T lymphocytes.47
This novel antibody class has the capability to redirect 
T cells and accessory cells, eg, macrophages, dendritic cells, 
and natural killer cells, to the tumor site after its activation 
by regulated intramembrane proteolysis.48–50
In a two-arm, randomized, open-label phase II/III study 
(NCT00836654) in patients with malignant and symptomatic 
ascites due to epithelial tumors, a reduction of necessary 
paracentesis was observed for the treatment arm. However, 
no significant increase of overall survival was reported.
Nimotuzumab (TheraCiM®, Theraloc®)
Nimotuzumab is a recombinant humanized murine IgG1 
mAb that blocks both EGF and transforming growth factor. 
  Compared to other EGFR-targeting antibodies, nimotuzumab 
has a slightly lower binding affinity, which is thought to 
account for an improved side-effect profile.
Several clinical trials are in progress globally to evaluate 
nimotuzumab in different indications of solid tumors. The 
combination of nimotuzumab and concurrent chemoradio-
therapy has been approved in several countries for use in 
SCCHN, and is currently being studied in end-stage phase II 
and phase III trials for treating locally advanced esophageal 
cancer (NCT01249352, NCT01402180).
Another ongoing study is evaluating standard radio-
therapy plus concomitant and adjuvant nimotuzumab plus 
temozolomide versus standard radiotherapy plus concomi-
tant and adjuvant temozolomide in patients with newly 
diagnosed glioblastoma multiforma (NCT00753246). The 
study started in 2007 and the estimated completion date is 
August 2011.Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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Fc fragments
Aflibercept
The aflibercept molecule was originally synthesized as a 
fusion protein combining the constant region (Fc) of IgG1 
with the first three domains of VEGFR1. It was found to 
maintain impressive picomolar binding affinity to VEGF, 
and was thus called a VEGF-trap.
Potential treatment effects are currently being seen 
in ongoing phase III studies in patients with mCRC 
(NCT00561470), and as second-line treatment of patients 
with locally advanced or metastatic nonsmall cell lung   cancer 
(NCT00532155). In patients with metastatic androgen-
independent prostate cancer, a randomized double-blind 
phase III trial showed no improved survival after treatment 
with aflibercept added to gemcitabine in a planned interim 
analysis (NCT00519285).
AMG-386
AMG 386, used as a competitive inhibitor of angiogenesis, 
comprises a human IgG1 Fc fragment and peptide specificity 
towards the angiopoietins Ang-1 and Ang-2.
A placebo-controlled phase III study to determine 
whether treatment of paclitaxel plus AMG 386 is efficient 
in women with epithelial ovarian cancer, primary peritoneal 
cancer, or fallopian tube cancer (NCT01204749) will be 
completed in April 2017.
Summary
Advances in molecular biology and biotechnology have led 
to a new class of therapeutics, mAbs, designed to treat an 
increasing number of indications. The clear advantages of 
mAbs for treating solid tumors lies in a more tumor-specific, 
and even cell-specific approach, which can reduce adverse 
effects frequently observed during conventional therapies. 
However, despite the currently exploding number of new 
agents, mAbs as well as Fc fragments are far from being a 
magic bullet in tumor therapy, since they still exhibit their 
own treatment-related risks as well as clear limitations. This 
explains the increasing focus on developing more specific, 
fine-tuned, and personalized approaches to use these agents 
as a powerful device in oncological therapy. In the future, 
not only a growing number of relevant antigens may be 
discovered, but also combination with other approaches (eg, 
linking antibodies to radionuclides, immunostimulants, or 
toxins) may allow better tumor control and increase survival 
in a variety of cancers.
Due to the large body of primary literature about mAb 
therapy in solid tumors, only selected references are given, 
and results from recent publications and articles that were 
relevant to phase II and III studies are emphasized.
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